Combination Therapy as the First-Line Treatment for Pulmonary Arterial Hypertension

Synopsis: The AMBITION trial compared upfront combination therapy with tadalafil and ambrisentan, with each drug analyzed individually in treatment-naive WHO functional group II-III pulmonary arterial hypertension patients. Statistically significant improvements were seen in the mortality, hospitalization for worsening pulmonary hypertension, disease progression, and the clinical response. Source: Galie N, Barbera JA, Frost AE, et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med. 2015;373(9):834-844.
Source: Clinical Pulmonary Medicine - Category: Respiratory Medicine Tags: Pulmonary Trends Source Type: research